Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 549.16B | 501.76B | 614.64B | 592.01B | 579.77B |
Gross Profit | 549.16B | 501.76B | 614.64B | 592.01B | 579.77B |
EBITDA | 77.48B | 42.98B | 42.86B | 45.90B | 41.75B |
Net Income | 42.87B | 22.77B | 34.43B | 30.37B | 28.23B |
Balance Sheet | |||||
Total Assets | 1.77T | 1.56T | 1.51T | 1.38T | 1.26T |
Cash, Cash Equivalents and Short-Term Investments | 664.26B | 21.87B | 21.36B | 21.79B | 23.13B |
Total Debt | 52.60B | 40.26B | 46.20B | 47.43B | 60.34B |
Total Liabilities | 1.40T | 1.23T | 1.21T | 1.08T | 982.51B |
Stockholders Equity | 268.73B | 242.35B | 221.77B | 219.26B | 202.48B |
Cash Flow | |||||
Free Cash Flow | 83.59B | 66.98B | 65.08B | 110.35B | 59.83B |
Operating Cash Flow | 87.99B | 70.55B | 71.65B | 72.73B | 31.87B |
Investing Cash Flow | -77.60B | -70.93B | -73.28B | -81.56B | -51.37B |
Financing Cash Flow | 4.86B | -11.48B | 8.56B | -35.86B | 21.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | HK$372.91B | 5.39 | 17.85% | 4.55% | 4.62% | 81.63% | |
64 Neutral | $6.61B | 11.16 | 7.19% | 5.25% | 24.10% | 5.12% | |
― | $45.84B | 6.12 | 16.47% | 4.16% | ― | ― | |
― | $7.11B | 5.66 | 9.88% | 2.97% | ― | ― | |
― | $43.58B | 9.68 | 13.15% | 4.74% | ― | ― | |
― | €17.59B | 11.52 | 8.73% | 2.66% | ― | ― | |
75 Outperform | HK$183.32B | 4.70 | 26.08% | 5.09% | -43.77% | ― |
The People’s Insurance Company (Group) of China Limited announced the resignation of Mr. Wang Qingjian, a non-executive director, effective from July 1, 2025, due to age. Mr. Wang has been a significant contributor to the company’s development strategy and corporate governance since 2017. The board expressed gratitude for his diligent service. Additionally, Mr. Miao Fusheng will no longer perform his duties as a director, as noted in a separate announcement.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Co (Group) of China has announced the list of its directors and their roles, highlighting the structure of its board and special committees. This announcement provides insight into the company’s governance and strategic focus, which may influence its operational effectiveness and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced the successful passing of all proposed resolutions during its 2024 annual general meeting held on June 27, 2025. The resolutions covered various aspects such as financial accounts, profit distribution, and amendments to the Articles of Association, reflecting the company’s strategic planning and operational focus for the upcoming years. This approval signifies strong shareholder support and positions the company for continued growth and stability in the competitive insurance market.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced an update to its final cash dividend for the year ended December 31, 2024. The dividend, declared at RMB 0.117 per share, will be paid in Hong Kong dollars at a rate of HKD 0.12814335 per share, with the exchange rate set at RMB 1 to HKD 1.09524227. The ex-dividend date is set for July 4, 2025, with payment scheduled for August 8, 2025. This announcement may impact the company’s shareholder value and market positioning, as it reflects the company’s financial performance and commitment to returning value to its shareholders.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Co (Group) of China has announced the list of its directors and their respective roles within the company. This announcement includes the establishment of five special committees under the board of directors, each focusing on different strategic areas such as risk management, audit, and related party transactions, which could strengthen the company’s governance and operational oversight.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has announced its 2024 Annual General Meeting, scheduled for June 27, 2025, in Beijing. The meeting will address various resolutions, including the approval of financial accounts, profit distribution, and capital planning for the upcoming years. The AGM will also consider amendments to the company’s Articles of Association and procedural rules, reflecting strategic adjustments aimed at enhancing governance and operational efficiency.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced an update regarding its final cash dividend for the financial year ending December 31, 2024. The dividend is set at RMB 0.117 per share, with the payment date scheduled for August 8, 2025. The update includes details on shareholder approval, Hong Kong share register information, and withholding tax arrangements. This announcement reflects the company’s commitment to returning value to its shareholders and may impact its market positioning and investor relations.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced the successful passing of resolutions at its 2025 first extraordinary general meeting held on April 29, 2025. Key resolutions included the approval of the remuneration scheme for directors and supervisors for 2023 and the election of new directors to the board. The meeting complied with relevant legal and regulatory requirements, and no shareholders were required to abstain from voting.
The People’s Insurance Company (Group) of China Limited has proposed amendments to its Articles of Association, which were approved by its board of directors. These amendments are subject to approval at the company’s general meeting and by the National Financial Regulatory Administration. The changes aim to align the company’s governance with relevant laws and regulations, potentially impacting its operational framework and stakeholder relations.
The People’s Insurance Company (Group) of China Limited reported significant financial growth in its first quarterly report of 2025, with a 12.8% increase in total operating income and a 43.4% rise in net profit attributable to the owners compared to the previous year. This growth reflects a strong operational performance and improved market positioning, benefiting stakeholders and enhancing the company’s financial stability.
The People’s Insurance Company (Group) of China Limited has announced the scheduling of its 2025 First Quarter Results Announcement. This event will be conducted through a text interaction session on April 30, 2025, allowing investors to engage and have their questions addressed. This initiative reflects the company’s commitment to transparency and active communication with its stakeholders, potentially enhancing its market position and investor relations.